MGCD265 is a tyrosine kinase inhibitor that targets the MET, VEGFR-1, VEGFR-2, VEGFR-3, RON and TIE2 receptor tyrosine kinases, which appear to play key roles in tumour development and blood vessel formation (angiogenesis) and tumour survival. MGCD265 is currently in phase I single-agent clinical trials for solid tumour cancers and in phase II trials for solid tumours and NSCLC

June 21, 2017

prudect name : MGCD265 is a tyrosine kinase inhibitor that targets the MET, VEGFR-1, VEGFR-2, VEGFR-3, RON and TIE2 receptor tyrosine kinases, which appear to play key roles in tumour development and blood vessel formation (angiogenesis) and tumour survival. MGCD265 is currently in phase I single-agent clinical trials for solid tumour cancers and in phase II trials for solid tumours and NSCLC
MGCD-265

Synonyms: CAS NO: 875337-44-3Molecular Formula: C26H20FN5O2S2Molecular Weight: 517.60Purity: 98% minSolubility: In DMSOStorage: −20°C


web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18534219